If the news is to move into a fast track phase 3 to completion , which is perhaps the most probable outcome , I am hoping at this point, with the nation’s eyes now on therapeutics as the near term treatment/solution , the OWS and Cytodyn reach an agreement on funding. At this point I have no doubt on the drug’s eventual approval but now we get into a cash burn issue. Other sources of non dilutive cash would be the UK stepping up to pay for trials.
A reminder to all,if the verdict is to proceed with finishing the trial , we are still one of the very few this far along in the approval cycle. Sell the stock at your own risk..